Top Suppliers:I want be here
Related CAS#:
516-35-8 516-50-7
2410279-85-3 6009-98-9
1207294-24-3 75672-32-1
2432-85-1 2432-81-7
2432-46-4 11043-91-7
1331433-96-5 1158522-08-7
940364-43-2 134104-43-1
131615-57-1 6906-52-1
930439-75-1 484649-07-2
1114872-58-0 1018584-77-4

516-35-8

516-35-8 structure
516-35-8 structure
  • Name: Taurochenodeoxycholic acid
  • Chemical Name: taurochenodeoxycholic acid
  • CAS Number: 516-35-8
  • Molecular Formula: C26H45NO6S
  • Molecular Weight: 499.704
  • Catalog: Biochemical Plant extracts
  • Create Date: 2018-08-06 10:12:20
  • Modify Date: 2024-01-02 12:38:47
  • Taurochenodeoxycholic acid is one of the main bioactive substances of animals' bile acid.
Name taurochenodeoxycholic acid
Synonyms Chenyltaurine
2-{[(3α,5β,7α,8ξ,9ξ,14ξ)-3,7-Dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonic acid
Chenodeoxycholyltaurine
Chenodeoxytaurocholic acid
12-Deoxycholyltaurine
Ethanesulfonic acid, 2-[[(3α,5β,7α,8ξ,9ξ,14ξ)-3,7-dihydroxy-24-oxocholan-24-yl]amino]-
Chenodeoxycholoyltaurine
[3H]-Chenodeoxycholyltaurine
Taurochenodeoxycholic acid
12-Desoxycholyltaurine
Taurochenodesoxycholic acid
Description Taurochenodeoxycholic acid is one of the main bioactive substances of animals' bile acid.
Related Catalog
Target

Caspase

TNF-α

Human Endogenous Metabolite

Apoptosis

In Vitro Studies have suggested that taurochenodeoxycholic acid as a signaling molecule shows obvious anti-inflammatory and immune regulation properties. Taurochenodeoxycholic acid dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, PKC mRNA levels and activities are significantly augmented by taurochenodeoxycholic acid treatments. In addition, JNK, caspase-3 and caspase-8 mRNA expression levels and activities are increased by taurochenodeoxycholic acid[1].
In Vivo Taurochenodeoxycholic acid in dosages of 0.05 and 0.1g/kg can decrease the pulmonary coefficient in the model mice, taurochenodeoxycholic acid in dosages of 0.05 and 0.1g/kg reduce the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice, the expression level of MMP-9 increases, while it has no significant effects on MMP2[2]. Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation[3]. Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats[4].
Animal Admin Rats: Male Wistar rats are divided into six groups of ten each. Group 1 is normal rat (Sham), Group 2 received FCA only, Group 3 and Group 4 received FCA+Taurochenodeoxycholic acid (0.1 g/kg) and FCA+Taurochenodeoxycholic acid (0.2 g/kg), respectively, Groups 3 and 4 are treated beginning from day 0 of injection of FCA, Group 5 and Group 6 received FCA+Taurochenodeoxycholic acid (0.1 g/kg) and FCA+Taurochenodeoxycholic acid (0.2 g/kg), respectively, Group 5 and Group 6 are treated from 14 days after induction. All animals are treated with intragastrical administration and sacrificed after 28 days of induction[4].
References

[1]. Wang X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway. Eur J Pharmacol. 2016 Sep 5;786:109-15.

[2]. Zhou C, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak J Pharm Sci. 2013 Jul;26(4):761-5.

[3]. Uchida A, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997 May;272(5 Pt 1):G1249-57.

[4]. Liu M, et al. Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol. 2011 Dec;11(12):2150-8.
Density 1.2±0.1 g/cm3
Molecular Formula C26H45NO6S
Molecular Weight 499.704
Exact Mass 499.296753
PSA 132.31000
LogP 2.10
Index of Refraction 1.552
Storage condition -20°C
Precursor  2

DownStream  0


Chemsrc provides CAS#:516-35-8 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 516-35-8 | Chemsrc address: https://www.chemsrc.com/en/baike/765278.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved